Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus

被引：10

作者：

Burt, RK

Marmont, A

Arnold, R

Heipe, F

Firestein, GS

Carrier, E

Hahn, B

Barr, W

Oyama, Y

Snowden, J

Kalunian, K

Traynor, A

机构：

[1] Osped San Martino Genova, Ctr Trapianti Midollo Osseo, Genoa, Italy

[2] Univ Klinikum Campus Charite Mitte, Berlin, Germany

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Univ Calif Los Angeles, Los Angeles, CA USA

[5] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

来源：

BONE MARROW TRANSPLANTATION | 2003年 / 32卷 / Suppl 1期

关键词：

lupus; hematopoietic stem cell transplantation;

D O I：

10.1038/sj.bmt.1703943

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results. A phase III HSCT trial is being developed to confirm efficacy of HSCT vs continuing the currently accepted standard of care, intravenous pulse cyclophosphamide.

引用

收藏

页码：S49 / S51

页数：3

相关论文

共 22 条

[1] THE PROGNOSIS OF LUPUS NEPHRITIS IN AFRICAN-AMERICANS - A RETROSPECTIVE ANALYSIS [J].

BAKIR, AA ;

LEVY, PS ;

DUNEA, G .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (02) :159-171

[2] RECURRENT ACUTE LUPUS ERYTHEMATOSUS DISSEMINATUS - REPORT OF A CASE WHICH HAS SURVIVED 23 YEARS AFTER THE ONSET OF SYSTEMIC MANIFESTATIONS [J].

BENASHER, S .

ANNALS OF INTERNAL MEDICINE, 1951, 34 (01) :243-248

[3] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].

BOMBARDIER, C ;

GLADMAN, DD ;

UROWITZ, MB ;

CARON, D ;

CHANG, CH .

ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640

[4] Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].

Brodsky, RA ;

Petri, M ;

Smith, BD ;

Seifter, EJ ;

Spivak, JL ;

Styler, M ;

Dang, CV ;

Brodsky, I ;

Jones, RJ .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035

[5] Collection of hematopoietic stem cells from patients with autoimmune diseases [J].

Burt, RK ;

Fassas, A ;

Snowden, JA ;

van Laar, JM ;

Kozak, T ;

Wulffraat, NM ;

Nash, RA ;

Dunbar, CE ;

Arnold, R ;

Prentice, G ;

Bingham, S ;

Marmont, AM ;

McSweeney, PA .

BONE MARROW TRANSPLANTATION, 2001, 28 (01) :1-12

[6] Hematopoietic stem-cell transplantation for systemic lupus erythematosus [J].

Burt, RK ;

Traynor, A ;

RamseyGoldman, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (24) :1777-1778

[7] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].

Chan, TM ;

Li, FK ;

Tang, CSO ;

Wong, RWS ;

Fang, GX ;

Ji, YL ;

Lau, CS ;

Wong, AKM ;

Tong, MKL ;

Chan, KW ;

Lai, KN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162

[8] CORTICOTROPIN AND CORTISONE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS [J].

DUBOIS, EL ;

COMMONS, RR ;

STARR, P ;

STEIN, CS ;

MORRISON, R .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1952, 149 (11) :995-1002

[9] THE PATHOGENESIS AND PROGNOSIS OF LUPUS NEPHRITIS - INFORMATION FROM REPEAT RENAL BIOPSY [J].

ESDAILE, JM ;

JOSEPH, L ;

MACKENZIE, T ;

KASHGARIAN, M ;

HAYSLETT, JP .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (02) :135-148

[10]

ESDAILE JM, 1994, SPRINGER SEMIN IMMUN, V16, P337